Folgen
John P. Seibyl
John P. Seibyl
Institute for Neurodegenerative Disorders
Bestätigte E-Mail-Adresse bei indd.org
Titel
Zitiert von
Zitiert von
Jahr
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses
JH Krystal, LP Karper, JP Seibyl, GK Freeman, R Delaney, JD Bremner, ...
Archives of general psychiatry 51 (3), 199-214, 1994
40281994
MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder
JD Bremner, P Randall, TM Scott, RA Bronen, JP Seibyl, SM Southwick, ...
The American journal of psychiatry 152 (7), 973, 1995
23831995
Levodopa and the progression of Parkinson's disease
Parkinson Study Group
New England Journal of Medicine 351 (24), 2498-2508, 2004
22562004
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.
M Laruelle, A Abi-Dargham, CH Van Dyck, R Gil, CD D'Souza, J Erdos, ...
Proceedings of the National Academy of Sciences 93 (17), 9235-9240, 1996
16241996
The Parkinson progression marker initiative (PPMI)
K Marek, D Jennings, S Lasch, A Siderowf, C Tanner, T Simuni, C Coffey, ...
Progress in neurobiology 95 (4), 629-635, 2011
14752011
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort
A Abi-Dargham, R Gil, J Krystal, RM Baldwin, JP Seibyl, M Bowers, ...
American journal of psychiatry 155 (6), 761-767, 1998
11051998
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
RG Holloway, I Shoulson, S Fahn, K Kieburtz, A Lang, K Marek, ...
Archives of neurology 61 (7), 1044-1053, 2004
6752004
Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl) tropane and single photon emission computed tomography
RT Malison, LH Price, R Berman, CH van Dyck, GH Pelton, L Carpenter, ...
Biological psychiatry 44 (11), 1090-1098, 1998
6381998
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study
H Barthel, HJ Gertz, S Dresel, O Peters, P Bartenstein, K Buerger, ...
The Lancet Neurology 10 (5), 424-435, 2011
5952011
Clinical significance of neurological soft signs in schizophrenia: factor analysis of the Neurological Evaluation Scale
RA Sewell, EB Perry Jr, LP Karper, MD Bell, P Lysaker, JL Goulet, ...
Schizophrenia research 124 (1-3), 1-12, 2010
5632010
Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease
JP Seibyl, KL Marchek, D Quinlan, K Sheff, S Zoghbi, Y Zea‐Ponce, ...
Annals of Neurology: Official Journal of the American Neurological …, 1995
5621995
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts
O Hansson, J Seibyl, E Stomrud, H Zetterberg, JQ Trojanowski, T Bittner, ...
Alzheimer's & dementia 14 (11), 1470-1481, 2018
5422018
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study
O Sabri, MN Sabbagh, J Seibyl, H Barthel, H Akatsu, Y Ouchi, K Senda, ...
Alzheimer's & dementia 11 (8), 964-974, 2015
4842015
Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease.
RB Innis, JP Seibyl, BE Scanley, M Laruelle, A Abi-Dargham, E Wallace, ...
Proceedings of the National Academy of Sciences 90 (24), 11965-11969, 1993
4811993
[sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease
KL Marek, JP Seibyl, SS Zoghbi, Y Zea-Ponce, RM Baldwin, B Fussell, ...
Neurology 46 (1), 231-237, 1996
4601996
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease
JH Kang, DJ Irwin, AS Chen-Plotkin, A Siderowf, C Caspell, CS Coffey, ...
JAMA neurology 70 (10), 1277-1287, 2013
4192013
[123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression
K Marek, R Innis, C Van Dyck, B Fussell, M Early, S Eberly, D Oakes, ...
Neurology 57 (11), 2089-2094, 2001
4142001
The role of radiotracer imaging in Parkinson disease
B Ravina, D Eidelberg, JE Ahlskog, RL Albin, DJ Brooks, M Carbon, ...
Neurology 64 (2), 208-215, 2005
3852005
Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects
AD Joshi, MJ Pontecorvo, CM Clark, AP Carpenter, DL Jennings, ...
Journal of Nuclear Medicine 53 (3), 378-384, 2012
3662012
The Parkinson's progression markers initiative (PPMI)–establishing a PD biomarker cohort
K Marek, S Chowdhury, A Siderowf, S Lasch, CS Coffey, ...
Annals of clinical and translational neurology 5 (12), 1460-1477, 2018
3622018
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20